Literature DB >> 12972310

Limitation of conventional two dimensional radiation therapy planning in nasopharyngeal carcinoma.

John Waldron1, Mo Mo Tin, Anne Keller, Cheemun Lum, Barbara Japp, Susanna Sellmann, Monique van Prooijen, Leah Gitterman, Ralph Blend, David Payne, Fei-Fei Liu, Padraig Warde, Bernard Cummings, Melania Pintilie, Brian O'Sullivan.   

Abstract

PURPOSE: To assess the adequacy of coverage of gross tumor volume (GTV) with traditional two dimensional (2D) radiation therapy (RT) planning in patients with nasopharyngeal cancer (NPC).
MATERIALS AND METHODS: The study comprised 94 of 179 patients treated with definitive RT between 1993 and 1997. The inclusion requirement was the availability of a digitally archived pretreatment magnetic resonance imaging. The digital images were used to record the precise location of the GTV in the sagittal plane. As a separate procedure, sagittal dose distributions for each treatment phase were created by digitizing the simulation field parameters into treatment planning software without knowledge of the GTV. The location of the GTV and dose distribution in the sagittal plane were superimposed on each other and GTV coverage by the 50, 90 and 95% isodose lines determined for each phase of treatment.
RESULTS: The 1997 tumour node metastasis (TNM) stage distribution was: 7 (8%) stage I, 16 (16%) stage II, 30 (32%) stage III and 41 (44%) stage IV. Median follow-up was 4.4 years. Median primary dose was 66 Gy. The actuarial 5-year overall survival, disease free survival and local relapse free rates were 88, 54 and 66%, respectively. The GTV was covered by the 50, 90 and 95% isodose lines for all phases of the multiphase plan in only 53, 20 and 9% of patients, respectively. The GTV was more likely to be undercovered in the latter phases of the plan particularly in those patients with advanced T category.
CONCLUSION: 2D RT planning has significant limitations in achieving adequate GTV coverage in NPC. We strongly recommend 3D planning using either conformal techniques of dose delivery or intensity modulated radiation therapy for the treatment of these patients.

Entities:  

Mesh:

Year:  2003        PMID: 12972310     DOI: 10.1016/s0167-8140(02)00370-5

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  9 in total

1.  Slug inhibition increases radiosensitivity of nasopharyngeal carcinoma cell line C666-1.

Authors:  Hongxia Yang; Gang Zhang; Xiaolin Che; Shudong Yu
Journal:  Exp Ther Med       Date:  2018-02-07       Impact factor: 2.447

2.  A benchmark study on 883 nasopharyngeal cancer patients treated in two Italian centres from 1977 to 2000. Part I: Evolving technical choices and survival.

Authors:  S Tonoli; S M Magrini; L Costa; F Paiar; G Simontacchi; V Scotti; N Pasinetti; R Barca; D Barbieri; A De Stefani; E Cellai; M Buglione; G Biti
Journal:  Radiol Med       Date:  2011-11-17       Impact factor: 3.469

3.  Current management strategy of nasopharyngeal carcinoma.

Authors:  William I Wei; Dora L W Kwong
Journal:  Clin Exp Otorhinolaryngol       Date:  2010-03-30       Impact factor: 3.372

4.  10-Year Results of Therapeutic Ratio by Intensity-Modulated Radiotherapy Versus Two-Dimensional Radiotherapy in Patients with Nasopharyngeal Carcinoma.

Authors:  Lei Chen; Yuan Zhang; Shu-Zhen Lai; Wen-Fei Li; Wei-Han Hu; Rui Sun; Li-Zhi Liu; Fan Zhang; Hao Peng; Xiao-Jing Du; Ai-Hua Lin; Ying Sun; Jun Ma
Journal:  Oncologist       Date:  2018-08-06

5.  Tumor suppressor BLU promotes TRAIL-induced apoptosis by downregulating NF-κB signaling in nasopharyngeal carcinoma.

Authors:  Jiahui Zhou; Zunnan Huang; Ziyou Wang; Shumin Liu; Alf Grandien; Ingemar Ernberg; Zhiwei He; Xiangning Zhang
Journal:  Oncotarget       Date:  2017-07-04

Review 6.  Progression of understanding for the role of Epstein-Barr virus and management of nasopharyngeal carcinoma.

Authors:  Yosuke Nakanishi; Naohiro Wakisaka; Satoru Kondo; Kazuhira Endo; Hisashi Sugimoto; Miyako Hatano; Takayoshi Ueno; Kazuya Ishikawa; Tomokazu Yoshizaki
Journal:  Cancer Metastasis Rev       Date:  2017-09       Impact factor: 9.264

7.  Individualized concurrent chemotherapy by pretreatment plasma Epstein-Barr viral DNA in II-III stage nasopharyngeal carcinoma: A propensity score matching analysis using a large cohort.

Authors:  Xue-Song Sun; Wen-Hui Chen; Sai-Lan Liu; Yu-Jing Liang; Qiu-Yan Chen; Shan-Shan Guo; Yue-Feng Wen; Li-Ting Liu; Hao-Jun Xie; Qing-Nan Tang; Xiao-Yun Li; Jin-Jie Yan; Hai-Qiang Mai; Lin-Quan Tang
Journal:  Cancer Med       Date:  2019-06-18       Impact factor: 4.452

8.  Comparison of the efficacy between intensity-modulated radiotherapy and two-dimensional conventional radiotherapy in stage II nasopharyngeal carcinoma.

Authors:  Xin-Bin Pan; Kai-Hua Chen; Shi-Ting Huang; Yan-Ming Jiang; Jia-Lin Ma; Zhong-Guo Liang; Song Qu; Ling Li; Long Chen; Xiao-Dong Zhu
Journal:  Oncotarget       Date:  2017-04-27

9.  The plasma Epstein-Barr virus DNA level guides precision treatment for nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: a large population-based cohort study from an endemic area.

Authors:  Hu Liang; Xing Lv; Lin Wang; Yi-Shan Wu; Rui Sun; Yan-Fang Ye; Liang-Ru Ke; Qin Yang; Ya-Hui Yu; Wen-Ze Qiu; Guo-Ying Liu; Xin-Jun Huang; Wang-Zhong Li; Shu-Hui Lv; Xiang Guo; Yan-Qun Xiang; Wei-Xiong Xia
Journal:  Ther Adv Med Oncol       Date:  2018-07-20       Impact factor: 8.168

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.